Skip to main content
    M

    Milestone Pharmaceuticals Inc (MIST)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.36
    -0.16 (-29.81%)

    Market Cap: $64.74M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Milestone Pharmaceuticals Inc (MIST) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Milestone Pharmaceuticals (MIST) to earn -$0.84 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.49M. Of 7 analysts, 6 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.

    RatingAnalystsShare
    Strong Buy114.3%
    Buy571.4%
    Hold114.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    7

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 461.9%.

    Fiscal year ending Dec 31, 2026
    -$0.84
    EPS consensus, revenue $3.49M
    Fiscal year ending Dec 31, 2027
    -$0.78
    EPS consensus, revenue $19.61M
    Next report
    Mar 18, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.84-$0.90 to -$0.775$3.49M$2.80M to $5.30M7
    Dec 31, 2027-$0.78-$0.96 to -$0.595$19.61M$8.80M to $34.60M7

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.23-$0.26 to -$0.219$1.85M$1.08M to $3.15M9

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.83.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.84-$0.84-$0.84-$0.84-$0.83N/A
    Fiscal year ending Dec 31, 2027-$0.78-$0.78-$0.77-$0.77-$0.91N/A

    Frequently Asked Questions About MIST

    What is the MIST stock forecast?

    Consensus analyst estimates put Milestone Pharmaceuticals's EPS at -$0.84 for the fiscal year ending Dec 31, 2026, on revenue of $3.49M. The consensus rating from 7 analysts is Buy.

    How do analysts rate MIST stock?

    Of 7 analysts covering Milestone Pharmaceuticals, 1 rates it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from MIST next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.84, with estimates from -$0.90 to -$0.77 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.78, with estimates from -$0.96 to -$0.59 from 5 analysts.

    What revenue do analysts expect from Milestone Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.49M, with estimates from $2.80M to $5.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $19.61M, with estimates from $8.80M to $34.60M.

    How many analysts cover MIST?

    7 analysts rate Milestone Pharmaceuticals stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.